In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. Epidermal Growth Factor Receptor gene (EGFR) Tests are carried out to detect mutations within this receptor gene in Non-Small Cell Lung Cancer (NSCLC) tumor cells; the outcome of which may determine if EGFR-targeted tyrosine kinase inhibitors such as gefitinib and erlotinib may be beneficial for treating NSCLC. GlobalData uses proprietary data and analytics to provide a comprehensive report on the egfr tests devices market, including market shares of different players within Italy. Buy the latest report here.
In 2023, GlobalData’s Market Model methodology determined that the leading player in the egfr tests market in Italy was Qiagen followed by F. Hoffmann-La Roche, Mesa Laboratories, Amoy Diagnostics, Thermo Fisher Scientific, Abbott Laboratories, NimaGen and Agilent Technologies.
The EGFR Tests includes EGFR Immunohistochemistry Tests, EGFR Nucleic Acid Amplification Tests (NAATs), EGFR Sanger Sequencing Tests, and EGFR Other Tests which include In Situ Hybridisation (ISH) and Mass Array.
The value of the egfr tests devices market within Italy was expected to be over $0.4m in 2023.
For the latest complete market share analysis of egfr tests device market in Italy, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.